Upgrade to SI Premium - Free Trial

Moleculin Biotech (MBRX)

7.09 +0.59 (9.08%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/9/26)

Latest Headlines

Form 8-K Moleculin Biotech, Inc. For: Oct 16 October 20, 2026 7:21 PM - SEC Filing Moleculin CEO discusses Annamycin MIRACLE trial progress October 20, 2026 8:12 AM - StreetInsider Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial October 20, 2026 8:12 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Oct 16 October 20, 2026 7:00 AM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Oct 15 Filed by: PICKER DONALD H October 16, 2026 9:01 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Oct 15 Filed by: KLEMP WALTER V October 16, 2026 9:01 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Oct 15 Filed by: Foster Jonathan P. October 16, 2026 9:00 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Oct 16 October 16, 2026 9:30 AM - SEC Filing Moleculin Biotech sets 1-for-20 reverse stock split for Oct. 20 October 16, 2026 9:20 AM - StreetInsider Moleculin Announces Reverse Stock Split October 16, 2026 9:20 AM - StreetInsider Form S-8 Moleculin Biotech, Inc. October 15, 2026 5:01 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Oct 09 October 9, 2026 5:16 PM - SEC Filing Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit October 7, 2026 8:45 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Oct 05 October 5, 2026 8:30 AM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Sep 29 September 29, 2026 8:45 AM - SEC Filing Moleculin completes Part A enrollment in AML trial, eyes Q1 2027 data September 29, 2026 8:45 AM - StreetInsider Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout September 29, 2026 8:45 AM - StreetInsider Moleculin publishes cardiac safety analysis of Annamycin in five trials September 28, 2026 7:01 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Sep 28 September 28, 2026 7:00 AM - SEC Filing Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine September 28, 2026 7:00 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Sep 25 September 25, 2026 1:05 PM - SEC Filing Moleculin preclinical data links Annamycin to immune response in pancreatic cancer September 25, 2026 1:05 PM - StreetInsider Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR September 25, 2026 1:05 PM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Sep 23 September 23, 2026 8:25 AM - SEC Filing Moleculin Biotech receives Mexican patent for Annamycin until 2040 September 23, 2026 8:25 AM - StreetInsider Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 September 23, 2026 8:25 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Sep 15 September 18, 2026 5:01 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Sep 14 September 14, 2026 4:00 PM - SEC Filing Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings September 14, 2026 8:35 AM - StreetInsider Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand September 11, 2026 8:30 AM - StreetInsider Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference August 27, 2026 9:01 AM - StreetInsider Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: Foster Jonathan P. August 25, 2026 4:24 PM - SEC Filing Form SCHEDULE 13D Moleculin Biotech, Inc. Filed by: KLEMP WALTER V August 25, 2026 4:23 PM - SEC Filing Form DEFA14A Moleculin Biotech, Inc. August 24, 2026 5:11 PM - SEC Filing Form DEF 14A Moleculin Biotech, Inc. For: Oct 09 August 24, 2026 5:01 PM - SEC Filing Form 424B5 Moleculin Biotech, Inc. August 21, 2026 5:16 PM - SEC Filing Form PRE 14A Moleculin Biotech, Inc. For: Oct 09 August 14, 2026 5:07 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Aug 14 August 14, 2026 8:31 AM - SEC Filing Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial August 14, 2026 8:30 AM - StreetInsider Form 10-Q Moleculin Biotech, Inc. For: Jun 30 August 13, 2026 4:18 PM - SEC Filing Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: CVI Investments, Inc. August 10, 2026 6:38 PM - SEC Filing Form SCHEDULE 13G Moleculin Biotech, Inc. Filed by: INTRACOASTAL CAPITAL, LLC August 6, 2026 5:27 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Aug 03 Filed by: Foster Jonathan P. August 5, 2026 4:21 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Aug 03 Filed by: KLEMP WALTER V August 5, 2026 4:20 PM - SEC Filing Form 4 Moleculin Biotech, Inc. For: Aug 03 Filed by: PICKER DONALD H August 5, 2026 4:19 PM - SEC Filing Form 8-K Moleculin Biotech, Inc. For: Jul 31 August 3, 2026 5:12 PM - SEC Filing Form 424B5 Moleculin Biotech, Inc. August 3, 2026 9:48 AM - SEC Filing Form EFFECT Moleculin Biotech, Inc. August 3, 2026 6:08 AM - SEC Filing Moleculin prices $9.3M public offering at $0.75 per share July 31, 2026 10:12 AM - StreetInsider Moleculin Announces Pricing of $9.3 Million Public Offering  July 31, 2026 10:12 AM - StreetInsider Moleculin reports 37% blinded remission rate in AML trial interim data July 31, 2026 8:10 AM - StreetInsider Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients July 31, 2026 8:10 AM - StreetInsider Form 8-K Moleculin Biotech, Inc. For: Jul 31 July 31, 2026 8:00 AM - SEC Filing Form S-1/A Moleculin Biotech, Inc. July 31, 2026 6:04 AM - SEC Filing Form S-1/A Moleculin Biotech, Inc. July 30, 2026 5:06 PM - SEC Filing Form S-1 Moleculin Biotech, Inc. July 29, 2026 9:41 AM - SEC Filing Full Article List